Menu Search
Equities

Medtronic PLC

MDTN:MEX

Medtronic PLC

Actions
Health CareHealth Care Equipment & Services
  • Price (MXN)2,245.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change37.14%
  • Beta0.6033
Data delayed at least 20 minutes, as of Jan 16 2020 19:25 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

  • Revenue in USD (TTM)30.89bn
  • Net income in USD4.62bn
  • Incorporated2014
  • Employees90.07k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MDT:NYQ since
announced		Transaction
value
Stimgenics LLCDeal completed08 Jan 202008 Jan 2020Deal completed4.10%--
Klue Labs IncDeal completed17 Dec 201917 Dec 2019Deal completed4.05%--
Titan Spine IncDeal completed09 May 201909 May 2019Deal completed33.91%--
Data delayed at least 15 minutes, as of Jan 28 2020 23:30 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.